Navigation Links
New test announced for major killer of lung transplant patients
Date:12/30/2010

ANN ARBOR, Mich. A lung transplant can mean a new chance at life. But many who receive one develop a debilitating, fatal condition that causes scar tissue to build up in the lungs and chokes off the ability to breathe.

University of Michigan researchers hope a new diagnostic tool they developed to predict bronchiolitis obliterans syndrome (BOS) will allow doctors to intervene earlier and, ultimately, to provide life-saving treatments.

BOS is the leading cause of death for those who survive one year after lung transplantation and more than half of recipients will develop BOS within five years. There is currently no cure.

Vibha Lama, M.D., M.S., an assistant professor of pulmonary and critical care medicine at the University of Michigan Medical School, led a team of U-M researchers who recently discovered that patients who had a high number of stem cells in their lungs six months after transplantation were much more likely to develop BOS than those with lower counts.

"Our study provides the first indication of the important role these cells play in both human repair and disease," Lama says. "It's very important from the clinical perspective because we didn't previously have any strong biomarkers for BOS."

The findings were recently published online ahead of print publication in the American Journal of Respiratory and Critical Care Medicine.

The translational study also highlights the importance of the lab-to-bedside cooperation of basic and clinical research, Lama says.

While the exact relationship between the mesenchymal stromal cells and BOS remains unclear, doctors know that most of the cells originate with the donor and not the recipient. Spikes in cell counts are seen shortly after transplantation as the body responds to the injury; those levels usually taper off, but a second rise of cell counts after about six months is linked to a patient's likelihood of developing BOS.

In 2007, Lama and her colleagues published another discovery about the stem cells, revealing that the cells reside in the transplanted organs, independent of their more commonly known association with bone marrow. That study led to the further exploration of the cells' involvement with chronic transplant rejection.

The new findings also have the potential to spur research that will help people suffering from other types of lung disease, such as idiopathic pulmonary fibrosis, known as IPF.

Having the biomarker will also allow researchers to readily identify a population of patients ideal for testing new drug interventions and therapies.

"By the time we usually diagnose BOS, there's already been a huge decline in lung function," Lama says. "If we can find the disease early, we can potentially do something about it."


'/>"/>

Contact: Ian Demsky
idemsky@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Autism Consortium 2010 Symposium: New therapeutics focus, family resource guide announced
2. Popular Mechanics breakthrough awardees announced
3. MARC Travel Awards announced for the 2010 Integrative Physiology of Exercise Meeting
4. Significant advance announced in treatment of cervical cancer
5. Civil society and local partners for XIX International AIDS Conference (AIDS 2012) announced
6. State of the Art Hospital for Rural Kenya Announced by California Foundation
7. New Health Reform Law Claim Denial Appeal Book Announced for Healthcare Providers to Comply with New PPACA Deadline - 09/23/2010
8. KFx Medical Corporation Announced Today It Has Received FDA 510k Clearance for Product(s) Used in a Wide Variety of Knee Procedures
9. 2010 OTC National Advertising Award Winners Announced
10. Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery'
11. SIUE Pain Summit Recommendations Announced Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Las Vegas, Nevada (PRWEB) , ... February 09, ... ... is now providing treatment to Medicaid beneficiaries who are diagnosed with autism spectrum ... state of Nevada. Autism treatment using applied behavior analysis (ABA) is key ...
(Date:2/9/2016)... ... February 09, 2016 , ... A ... fee schedule rates and Medicare rates for a variety of medical services in ... Evaluation of the 2015 Fee Schedule Rates in Illinois, are professional ...
(Date:2/9/2016)... York, NY (PRWEB) , ... February 09, 2016 , ... ... the appointment of Dr. David Hung to the company´s Board of Directors. ... a world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO ...
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic ... Teeth whitening is among the most popular cosmetic procedures in dentistry today, but the ... This can put them at risk of teeth whitening-related damage. For a limited time, ...
(Date:2/9/2016)... ... 2016 , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter ... June 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of ... in 2015, the Maui Photo Expedition workshop will once again consist of ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Mass. , Feb. 9, 2016  Insulet Corporation (NASDAQ: ... tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s Board ... of nine directors, eight of whom are independent. ... 40 years of audit and finance experience and a deep ...
(Date:2/9/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... fourth quarter and full year 2015 financial results ... genome editing," said Edward Lanphier, Sangamo,s president and ... technology leads the therapeutic genome editing field and ... move our ground-breaking genome editing programs through IND ...
(Date:2/9/2016)... 9, 2016  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... fourth quarter and full year financial results on Tuesday, ... markets.  Company management will host a live audio webcast ... GMT to discuss fourth quarter and full year 2015 ... and guidance for 2016 financial results. www.jazzpharmaceuticals.com ...
Breaking Medicine Technology: